Penicillin-binding protein 1A mutation-positive Helicobacter pylori promotes epithelial-mesenchymal transition in gastric cancer via the suppression of microRNA-134

LU HUANG1*, ZHI-YONG WANG2* and DAO-DONG PAN1,3

1 College of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210023; 2 Department of Surgical Oncology, Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of TCM, Nanjing, Jiangsu 214504; 3 School of Marine Science, Ningbo University, Ningbo, Zhejiang 315211, P.R. China

Received June 11, 2018; Accepted August 24, 2018

DOI: 10.3892/ijo.2018.4665

Abstract. Evidence suggests that Helicobacter pylori (H. pylori) is not only the main cause of gastric cancer (GC), but is also closely associated with its metastasis. One of the major virulence factors in H. pylori is the cytotoxin-associated gene A (CagA). With the growing proportion of amoxicillin-resistant H. pylori strains, the present study aimed to explore the effects of CagA- and penicillin-binding protein 1A (PBP1A) mutation-positive H. pylori (H. pyloriCagA+/P+) on GC cells, and its clinical significance. The clinical significance of H. pyloriCagA+/P+ infection was analyzed in patients with GC. In vitro, GC cells were infected with H. pyloriCagA+/P+, to investigate whether it was involved in the epithelial-mesenchymal transition (EMT) of SGC-7901 cells using immunofluorescence and western blot analysis. The results of clinical analysis demonstrated that, although CagA-negative H. pylori infection had no significant association with the characteristics of patients with GC, H. pyloriCagA+/P+ infection was significantly associated with various clinicopathological parameters, including invasion depth, lymphatic metastasis and distant metastasis. In vitro, the results indicated that H. pyloriCagA+/P+ promoted proliferation, invasion and EMT of SGC-7901 cells. MicroRNA (miR)-134 was downregulated in H. pyloriCagA+/P+ infected tissues compared with in those with H. pyloriCagA+/P-. miR-134 overexpression significantly reversed H. pyloriCagA+/P+ infection-associated cell proliferation, invasion and EMT. Furthermore, the results revealed that Forkhead box protein M1 (FoxM1) was a direct target of miR-134, and FoxM1 knockdown impeded H. pyloriCagA+/P+-induced EMT. In conclusion, the present study demonstrated that miR-134 may suppress the proliferation, invasion and EMT of SGC-7901 cells by targeting FoxM1, and may serve a protective role in the process of H. pyloriCagA+/P+-induced GC. These findings may lead to an improved understanding of H. pyloriCagA+/P+-associated poor clinical characteristics in patients with GC.

Introduction

Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic bacterium that colonizes the gastric mucosa and infects ~50% of individuals worldwide. It has been categorized as a group I carcinogen for gastric cancer (GC) by the World Health Organization, and GC remains a major public health problem worldwide (1,2). A previous study revealed that the relative risk for the development of GC was 3.8-fold higher in patients with H. pylori infection compared to those without (3). In addition, the association between H. pylori eradication and the reduced incidence of GC has been demonstrated in a meta-analysis study (4). Nevertheless, with regards to the prognosis of GC, several studies have suggested that H. pylori infection is a favorable prognostic factor of GC in a Chinese prospective cohort (5,6). Conversely, other studies have indicated that H. pylori infection has no association with prognosis in Chinese patients (7,8). It was hypothesized that this discrepancy may be due to the fact that GC with different H. pylori genotypes exhibits different growth patterns and pathobiological behavior, indicating different mechanisms of cancer progression. Further knowledge regarding H. pylori-infected GC may help to identify novel therapeutic targets.

Treatment of H. pylori infection is often empiric and current guidelines recommend against the use of standard triple therapy (clarithromycin, amoxicillin and proton pump inhibitors) as first-line treatment (9). However, the prevalence of amoxicillin-resistant H. pylori is very high in Africa (65.6%) and Asia (11.6%) (9,10). In H. pylori, resistance occurs through

*Contributed equally

Abbreviations: H. pylori, Helicobacter pylori; GC, gastric cancer; CagA, cytotoxin-associated gene A; PBP1A, penicillin-binding protein 1A; FoxM1, Forkhead box M1; miRNAs/miRs, microRNAs; EMT, epithelial-mesenchymal transition

Key words: gastric cancer, Helicobacter pylori, penicillin-binding protein 1A, microRNAs, epithelial-mesenchymal transition
modifications in penicillin-binding proteins (PBPs), leading to a decreased affinity for the drug. These modifications include mutations and/or mosaics in PBP2X and PBP2B, as well as in PBPIA for the highly resistant isolates (11). To date, the clinical significance of amoxicillin-resistant *H. pylori* (PBPIA mutation-positive *H. pylori*, *H. pylori*/*P+*) in GC, and the role of *H. pylori*/*P+* in GC cell malignant behavior and its specific mechanism require further elucidation. Furthermore, the *H. pylori* genome shows genetic diversity among distinct isolates, and *H. pylori* pathogenicity is different in distinct isolates. Clinically isolated *H. pylori* strains are often subdivided into two types according to the cytotoxin-associated gene (*Cag*) pathogenicity island-encoded CagA protein (12). Notably, CagA-positive *H. pylori* increases the risk for GC over the risk associated with *H. pylori* infection alone (13). In addition, it has been reported that infections involving *H. pylori* strains that possess the virulence factor CagA have a worse clinical outcome than those involving CagA-negative strains (14), and CagA is indispensable for *H. pylori*-induced tumorigenesis in GC (15). Furthermore, CagA may promote epithelial-mesenchymal transition (EMT), which indicates a strong ability to induce invasion and metastasis of tumor cells, and to stimulate gastric carcinogenesis (16). Therefore, in the present study, the role of CagA- and PBPIA mutation-positive *H. pylori* (*H. pylori*/*CagA+/*P+*) was investigated in patients with GC and in GC cells, in order to gain insights into the effects of *H. pylori* during the development of GC.

Factors intrinsic to the host may also contribute to the emergence of GC, and microRNAs (miRNAs/miRs) appear to serve an important role in the etiology of this disease (17). miRNAs are noncoding RNAs that are involved in post-translational regulation of gene expression (18). Unique miRNAs are associated with various histological subtypes, and the progression and prognosis of GC (19). A previous study demonstrated that *H. pylori* may induce dysregulation of miRNAs, contributing to the etiology of *H. pylori*-mediated GC cases (17). Therefore, the identification of signature miRNAs associated with *H. pylori* infection may provide novel insights into its carcinogenesis and the host mechanisms that are involved in bacterial elimination. However, whether miRNAs are involved in the effects of *H. pylori*/*CagA+/*P+* on GC has received little attention.

The present study investigated the clinical significance of *H. pylori*/*CagA+/*P+* in patients with GC, and explored the role of *H. pylori*/*CagA+/*P+* in cell proliferation, invasion and EMT of GC cells in vitro, in order to uncover the potential mechanism underlying the effects of *H. pylori*/*CagA+/*P+* on gastric carcinogenesis. Furthermore, the involvement of potential miRNAs in the pathogenesis of *H. pylori*/*CagA+/*P+*-associated GC was observed.

**Materials and methods**

Patients. *H. pylori* strains and culture conditions. The present study was conducted between February 2014 and November 2017 at the Jiangsu Province Hospital of TCM (Nanjing, China). Gastric biopsy specimens were collected and maintained in selective trypsic soy broth as transport media for further processing, as recommended by Siu et al (20). Only patients who were diagnosed with GC, and were negative or positive for *H. pylori* were recruited; patient characteristics are presented in Table I. A total of 184 pairs of GC tissues and adjacent non-tumor tissues were collected during surgery. None of the patients had received adjuvant chemotherapy, radiotherapy or *H. pylori* eradication treatment prior to surgery. The histological types, stages and types of treatment of the patients with GC were recorded. Samples obtained from each patient were collected for culture, and three clinical isolates were recovered from GC tissues, as previously described (21), which were used in the present study. Identification of *H. pylori* was determined by colony morphology, Gram-staining, and biochemical profile reactions, such as oxidase, catalase and urease tests (22). The molecular identification of CagA-positive and CagA-negative strains was conducted as previously described (23). The amoxicillin-susceptible and amoxicillin-resistant *H. pylori* strains examined in this study were isolated from GC tissues. Amoxicillin resistance was identified by sub-culturing swabs of bacteria from isolation plates to horse blood agar plates with and without 0.5 mg/l amoxicillin (Merck KGaA, Darmstadt, Germany), as previously described (24). A PBPIA mutation in the C-terminal region (encoded by amino acids 320-660) was validated using reverse transcription-polymerase chain reaction (RT-PCR) (22); the primers used were as follows: Forward, 5'-GCGACATCTGGATGAAAT-3' and reverse, 5'-CCATTGTTCACATAATCA-3'(22). All *H. pylori* strains were cultured on chocolate blood agar, and were incubated at 37°C in a humidified incubator containing 10% CO2 and 85% N2 for 48 h.

Cell culture. The human gastric epithelial cell line (GES-1), and GC cell lines, MGC-803, BGC-823, SGC-7901 and MKN45, were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA USA). 293T cells (Cell Bank of Chinese Academy of Sciences) were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO2.

*H. pylori* infection experiments. For cell infection, a single colony of a 3-day old culture was cultured in 5 ml broth (tryptone 10 g/l; yeast extract 5 g/l; NaCl 10 g/l in distilled water; pH 7.4) supplemented with 10% heat-inactivated FBS (Gibco; Thermo Fisher Scientific, Inc.). The bacterial cultures were incubated under microaerobic conditions generated by CampyGen sachets at 37°C for 1-2 days with agitation at 150 rpm. When the 600 nm optical density of the bacterial culture in Brain Heart Infusion broth (HiMedia Laboratories, Mumbai, India) reached 1.0, the bacteria were harvested and incubated at 37°C in RPMI medium for 30 min. SGC-7901 cells were microscopically enumerated using an improved Neubauer counting chamber. Monolayer SGC-7901 cells in a 6-well plate (102 well) were incubated with *H. pylori* at a multiplicity of infection of 50:1 for 12 h at 37°C and 10% CO2, as previously described (25).

**Cell transfection.** miRNA mimic control (5'-UCACAACCUC CUAGAAAGAGUAGA-3'), miR-134 mimics (sense 5'-UGU
Table I. Association between the clinical characteristics of the study subjects and the various *H. pylori* strains.

| Clinical characteristics | H. pylori-negative (n=50) | HP_CagA- (n=48) | HP_CagA+/P- (n=55) | HP_CagA+/P+ (n=31) | P<sup>a</sup> | P<sup>b</sup> | P<sup>c</sup> |
|--------------------------|---------------------------|----------------|-------------------|-------------------|------------|------------|------------|
| Age, years (means ± SD)  | 57.70±9.64                | 54.31±7.82     | 52.96±8.95        | 55.08±11.15       | 0.38       | 0.22       | 0.56       |
| Sex                      |                           |                |                   |                   |            |            |            |
| Male                     | 35                        | 27             | 30                | 19                | 0.23       | 0.98       | 0.70       |
| Female                   | 15                        | 21             | 25                | 12                |            |            |            |
| Location                 |                           |                |                   |                   |            |            |            |
| Proximal                 | 9                         | 11             | 16                | 7                 | 0.78       | 0.69       | 0.67       |
| Middle                   | 16                        | 16             | 19                | 10                |            |            |            |
| Distal                   | 25                        | 21             | 20                | 14                |            |            |            |
| Size                     |                           |                |                   |                   | 0.90       | 0.032      | 0.028      |
| ≤5 cm                    | 38                        | 36             | 23                | 5                 |            |            |            |
| ≥5 cm                    | 12                        | 12             | 32                | 26                |            |            |            |
| Histological classification |                         |                |                   |                   | 0.22       | 0.08       | 0.57       |
| Papillary adenocarcinoma | 11                        | 12             | 15                | 9                 |            |            |            |
| Tubular adenocarcinoma   | 26                        | 31             | 24                | 17                |            |            |            |
| Mucinous adenocarcinoma  | 5                         | 1              | 5                 | 2                 |            |            |            |
| Signet-ring cell carcinoma | 8                      | 4              | 11                | 3                 |            |            |            |
| Histological differentiation |                        |                |                   |                   | 0.19       | 0.25       | 0.14       |
| Well                     | 9                         | 17             | 23                | 9                 |            |            |            |
| Moderately               | 8                         | 9              | 16                | 6                 |            |            |            |
| Poorly                   | 31                        | 21             | 16                | 15                |            |            |            |
| Others                   | 2                         | 1              | 0                 | 1                 |            |            |            |
| Invasion depth           |                           |                |                   |                   | 0.21       | 0.006      | <0.0001    |
| T1                       | 13                        | 20             | 10                | 4                 |            |            |            |
| T2                       | 30                        | 19             | 20                | 2                 |            |            |            |
| T3                       | 5                         | 5              | 19                | 9                 |            |            |            |
| T4                       | 2                         | 4              | 6                 | 16                |            |            |            |
| TNM stages               |                           |                |                   |                   | 0.62       | 0.015      | 0.019      |
| I                        | 22                        | 18             | 11                | 6                 |            |            |            |
| II                       | 19                        | 23             | 20                | 4                 |            |            |            |
| III                      | 7                         | 4              | 20                | 13                |            |            |            |
| IV                       | 2                         | 3              | 4                 | 8                 |            |            |            |
| Lymphatic metastasis     |                           |                |                   |                   | 0.89       | 0.006      | 0.007      |
| No                       | 36                        | 33             | 24                | 4                 |            |            |            |
| Yes                      | 14                        | 15             | 31                | 27                |            |            |            |
| Distant metastasis       |                           |                |                   |                   | 0.27       | 0.008      | 0.009      |
| No                       | 33                        | 37             | 21                | 3                 |            |            |            |
| Yes                      | 17                        | 11             | 34                | 28                |            |            |            |

<sup>a</sup>χ² analysis between *H. pylori*-negative and HP_CagA- groups; <sup>b</sup>χ² analysis between HP_CagA+/P- and HP_CagA- groups. <sup>c</sup>χ² analysis between HP_CagA+/P- and HP_CagA+/P+ groups. CagA, cytotoxin-associated gene A; HP_CagA-, CagA-negative *H. pylori*; HP_CagA+/P-, CagA-positive and PBP1A mutation-negative *H. pylori*; HP_CagA+/P+, CagA- and PBP1A mutation-positive *H. pylori*; *H. pylori*, *Helicobacter pylori*; PBP1A, penicillin-binding protein 1A; SD, standard deviation.
to the manufacturer's protocol. Briefly, 5x10⁷ cells were seeded into each well of 6-well plates 18-24 h prior to transfection. The transfection medium (2 ml) containing 1 µg/ml siRNAs or 100 nmol/l miRNA mimics/inhibitors together with 6 µl Lipofectamine® 2000 was incubated at room temperature for 5 min and was then transferred to each well of the culture plates at 37°C; the cells were harvested for analysis after 24 h. FoxM1 overexpression was achieved by transfecting SGC-7901 cells with the FoxM1 (NM_202002) plasmid (Shanghai GeneChem Co., Ltd., Shanghai, China). Attractane transfection reagent (Qiagen GmbH, Hilden, Germany) was used to transfect cells with the FoxM1 plasmid or an empty GV230 plasmid (Shanghai GeneChem Co., Ltd.), in accordance with the manufacturer's protocol.

miRNA microarray analysis. Five CagA-positive and PBPla mutation-negative H. pylori (H. pylori CagA+/P-) and five H. pylori CagA+/P+ tumor tissue samples were selected for miRNA microarray analysis. Total RNA was isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and miRNeasy mini kit (Qiagen GmbH), according to the manufacturers' protocols. Total RNA was then labeled using the miRCURY™ Array Power labeling kit (Exiqon; Qiagen GmbH) and hybridization was performed using miRCURY™ LNA Array (Exiqon; Qiagen GmbH). Fluorescent images were collected using a laser scanner (GenePix 4000B; Molecular Devices, LLC, Sunnyvale, CA, USA) and were digitized using Array-Pro image analysis software 6.3 (Media Cybernetics, Inc., Rockville, MD, USA). The SpotData Pro 3.0 software (CapitalBio Corporation, Beijing, China) was used for data analysis. Hierarchical clustering was performed using Data Matching Software MeV v4.8.1 (26).

RNA extraction and RT-quantitative (q)PCR analysis. Total RNA was isolated from the treated cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed using the cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's protocol, and quantification was performed using SYBR Green (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturers' protocols. Total RNA was then labeled using the miRCURY™ Array Power labeling kit (Exiqon; Qiagen GmbH) and hybridization was performed using miRCURY™ LNA Array (Exiqon; Qiagen GmbH). Fluorescent images were collected using a laser scanner (GenePix 4000B; Molecular Devices, LLC, Sunnyvale, CA, USA) and were digitized using Array-Pro image analysis software 6.3 (Media Cybernetics, Inc., Rockville, MD, USA). The SpotData Pro 3.0 software (CapitalBio Corporation, Beijing, China) was used for data analysis. Hierarchical clustering was performed using Data Matching Software MeV v4.8.1 (26).

Luciferase assay and constructs. TargetScan (http://www.targetscan.org) and microRNA database (http://www.microrna.org) bioinformatics software were used to predict the downstream targets of miR-134. The FoxM1 promoter region was amplified from human genomic DNA (cat. no. Roche-1169112001; Sigma-Aldrich; Merck KGaA) for 15 min at room temperature and stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature. Cells were visually counted in five randomly selected fields under a light microscope (Axiovert 200 inverted microscope; Zeiss AG, Oberkochen, Germany).

Cell proliferation and invasion. Cell proliferation was measured using the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). At different time points, 10 µl CCK-8 solution was added to each well, and the plates were incubated at 37°C for 2 h. Absorbance was measured at 570 nm using a Thermo Fisher Scientific Microplate Reader (Thermo Fisher Scientific, Inc.). The cell invasion assay was performed using Transwell chambers coated with Matrigel (EMD Millipore, Billerica, MA, USA). At 48 h post-transfection, 10⁴ cells were added into the upper chambers alongside serum-free medium. In the lower chambers, 500 µl RPMI-1640 medium containing 10% FBS was added as a chemoattractant. After 24 h, the Matrigel and cells on the upper surface were removed by cotton swabs, and the cells that had migrated to the lower surface were fixed in 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature and stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature. Cells were visually counted in five randomly selected fields under a light microscope (Axiovert 200 inverted microscope; Zeiss AG, Oberkochen, Germany).
luminescence intensity were calculated by comparison with the mimic control-transfected cells.

**Immunofluorescence analysis.** After treatment, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature and blocked with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. The cells were then incubated with E-cadherin (1:400), α-SMA (1:500) or FoxM1 (1:500) primary antibodies overnight at 4°C. After washing with PBS-0.1% Tween, cells were incubated with Alexa Fluor® 488 goat anti-rabbit IgG (cat. no. A-11034) or Alexa Fluor® 594 goat anti-rabbit IgG (cat. no. B40925; 1:500; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at room temperature in the dark. DAPI (Sigma-Aldrich; Merck KGaA) was used to identify the nuclei. Images were captured under a Nikon Eclipse 800 epifluorescence microscope (Nikon Corporation, Tokyo, Japan) with the appropriate filters.

**Statistical analysis.** All experiments were performed at least three times and data are presented as the means ± standard error. Pearson’s $\chi^2$ test was used to investigate the associations between *H. pylori* status and categorical variables. Student’s t-test was used to compare differences between two groups with continuous variables. One-way analysis of variance and least significant difference post hoc test was used to compare the differences between more than two groups. Pearson’s correlation was used to analyze the relationship between miR-134 and FoxM1 expression. Statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). P < 0.05 was considered to indicate a statistically significant difference.

## Results

*H. pylori* CagA+/P+ infection is associated with poor clinico-pathological characteristics in patients with GC. The study group consisted of 50 patients with *H. pylori*-negative GC, 48 patients with CagA-negative *H. pylori* (H. pylori CagA−), 55 patients with *H. pylori* CagA+/P−, GC, and 31 patients with *H. pylori* CagA+/P+. As shown in Table I, the demographic and
H. pylori infec-
tion reduced the fluorescence intensity of E-
cadherin, but increased the intensity of α-SMA (Fig. 1C). Western blot analysis indicated that H. pylori(CagA+/P+) infection induced EMT of SGC-7901 cells, whereas H. pylori(CagA+/P-) exhibited more prominent EMT in GC cells compared with the H. pylori(CagA+/P-) group (Fig. 1D). These findings may explain why patients with H. pylori(CagA+/P+) and GC exhibited advanced malignant behavior compared with patients with H. pylori(CagA+/P-) infection.

miR-134 is downregulated in H. pylori(CagA+/P+) GC tissues and cells. To determine the potential involvement of miRNAs in gastric carcinogenesis induced by H. pylori(CagA+/P-) and H. pylori(CagA+/P+), a miRNA microarray was performed on five GC tissues, which were randomly selected from the H. pylori(CagA+/P-) and H. pylori(CagA+/P+) groups. Notably, the results identified nine upregulated miRNAs and 11 downregulated miRNAs in the H. pylori(CagA+/P-) group compared with the H. pylori(CagA+/P+) group (Fig. 2A). The present study further investigated the four most downregulated miRNAs, miR-134, miR-218, miR-159 and miR-488, and validated the microarray results using RT-qPCR. The expression levels of miR-134 were decreased in the H. pylori(CagA+/P-) group compared with the control group, and were further decreased in the H. pylori(CagA+/P+) group (Fig. 2B). Although miR-218 and miR-488 were decreased in H. pylori-infected GC tissues, there was no significant difference between the different H. pylori strains (Fig. 2C and D). In addition, miR-159
miR-134 inhibits HP-induced cell proliferation, invasion and reverses EMT. In order to elucidate the relationship between miR-134 and *Helicobacter pylori*-induced malignant behavior of GC cells, proliferation, invasion and EMT of SGC-7901 cells were analyzed. As shown in Fig. 3A, miR-134 expression differed between GES-1 cells and the four GC cell lines. SGC-7901 cell exhibited the lowest miR-134 expression; therefore, it was then chosen for subsequent analyses. As presented in Fig. 3B, SGC-7901 cells exposed to *H. pylori* infection exhibited reduced miR-134 expression, and cells infected with *H. pylori* possessed the lowest expression levels of miR-134; these findings were consistent with the results from clinical samples. Therefore, SGC-7901 cells were transfected with miR-134 mimics to induce miR-134 overexpression (Fig. 3C). Subsequently, CCK-8 and Transwell assays demonstrated that miR-134 overexpression significantly decreased *H. pylori*-induced cell proliferation and invasion compared with the control group (Fig. 3D and E). As shown in Fig. 3F, miR-134 overexpression upregulated E-cadherin, and downregulated α-SMA expression. In addition, western blot analysis revealed consistent alterations in the aforementioned EMT markers in the *H. pylori*-infected group (Fig. 3G). These findings indicated that miR-134 may act as a suppressor of proliferation, invasion and EMT in *H. pylori*-infected SGC-7901 cells.

**FoxM1 is identified as a direct target of miR-134.** To determine the target gene of miR-134 in *H. pylori*-infected GC cells, candidate target genes were searched using bioinformatics analysis. The analysis revealed that FoxM1 possessed a putative miR-134-binding site (Fig. 4A), which prompted further validation of this relationship. FoxM1 expression was significantly increased in *H. pylori*-infected SGC-7901 cells (Fig. 4B). Correlation analysis revealed that FoxM1 expression was negatively correlated with miR-134 expression (Fig. 4C). Subsequently, knockdown of miR-134 was achieved via transfection with miR-134 inhibitors; transfection efficiency was validated by RT-qPCR (Fig. 4D). In response to miR-134 overexpression, the mRNA and protein expression levels of FoxM1 were significantly downregulated, whereas they were upregulated by miR-134 knockdown in SGC-7901 cells (Fig. 4E and F). Dual luciferase reporter assay revealed that miR-134 mimics significantly suppressed FoxM1 wild type luciferase activity compared with in the mimics control group, but did not affect FoxM1 mutant type luciferase activity (Fig. 4G). Furthermore, immunofluorescence assay demonstrated that miR-134 mimics decreased the expression of FoxM1 protein in *H. pylori*-infected cells (Fig. 4H). These data suggested that FoxM1 was a direct target gene of miR-134 and was negatively regulated by miR-134.

**Knockdown of FoxM1 impedes *H. pylori*-induced EMT.** Although elevated FoxM1 is identified as a prognostic factor for GC, whether it is involved in EMT in *H. pylori*-associated GC remains undefined. Therefore, si-FoxM1 was used to knockdown...
FoxM1 in *H. pylori* CagA+/P+-infected SGC-7901 cells. The transfection efficiency of si-FoxM1 was determined using RT-qPCR and western blot analysis (Fig. 5A and B). Subsequently, the role of FoxM1 in *H. pylori* CagA+/P+-induced EMT was determined. Western blot analysis revealed that *H. pylori*-mediated EMT was significantly reversed by knockdown of FoxM1 (Fig. 5C). Similarly, these findings were validated at the mRNA level, as evidenced by the alterations in EMT-associated genes (Fig. 5D-F). These data revealed that *H. pylori* CagA+/P+ may trigger EMT of GC cells through regulation of FoxM1.

**miR-134 exerts its tumor suppressor function through regulation of FoxM1.** Having demonstrated that FoxM1 is a target gene of miR-134, the present study further investigated whether it was involved in the miR-134-mediated role in *H. pylori* CagA+/P+-infected GC cells. A FoxM1 plasmid was transfected into SGC-7901 cells, and the mRNA and protein expression levels of FoxM1 were significantly increased following transfection (Fig. 6A and B). As illustrated in Fig. 6C and D, the inhibitory effects of miR-134 overexpression were reduced by co-transfection with FoxM1. Furthermore, western blotting (Fig. 6E) and RT-qPCR analysis (Fig. 6F-H) demonstrated that co-transfection with miR-134 mimics and FoxM1 markedly downregulated E-cadherin, and upregulated Vimentin and α-SMA compared with the *H. pylori* CagA+/P+ mimics control group. These data suggested that miR-134 may inhibit *H. pylori* CagA+/P+-induced GC cell proliferation and invasion, and reverse EMT by regulating FoxM1 in SGC-7901 cells.

**Discussion**

The present study demonstrated that *H. pylori* CagA+/P+ was associated with poor clinicopathological characteristics in GC. In addition, *H. pylori* CagA+/P+ infection significantly promoted GC cell proliferation and invasion, and induced...
EMT of GC cells. The present results also demonstrated that \(H.\ pylori_{CagA+/P_+}\) may promote GC cell malignant behavior through regulation of the miR-134/FoxM1 regulatory network. These data may help to further understand the role of \(H.\ pylori\) in gastric carcinogenesis.

Although the causal association between \(H.\ pylori\) infection and GC incidence is well established, the exact associations between \(H.\ pylori\) and the progression of GC remain largely unknown (28). The present study analyzed the association between \(H.\ pylori\) infection and the clinical characteristics of GC patients without \(H.\ pylori\) infection, and in GC patients with \(H.\ pylori_{CagA-}, H.\ pylori_{CagA+/P-}\), and \(H.\ pylori_{CagA+/P+}\) infection. The results indicated that \(H.\ pylori_{CagA-}\) infection was not significantly associated with patient characteristics. This finding was similar to the results of previous studies, which suggested that \(H.\ pylori\) infection has no association with prognosis in China, and the prognosis of \(H.\ pylori\)-negative GC is equally poor (29). However, the present study demonstrated that patients infected with \(H.\ pylori_{CagA+/P+}\) possessed a higher proportion of advanced characteristics than those with \(H.\ pylori_{CagA-}\). This result was also supported by the findings that patients with \(H.\ pylori_{CagA+}\), GC had a worse clinical outcome than those involving \(H.\ pylori\) strains (8).

Furthermore, distinct characteristics between \(H.\ pylori_{CagA+/P-}\) and \(H.\ pylori_{CagA+/P+}\) GC were observed. Therefore, the present study focused on the role of PBP1A-mutated \(H.\ pylori\) strains. In vitro-selected amoxicillin-resistant \(H.\ pylori\) strains, the resistance has been suggested to result from alterations in PBP1A (30,31). A single serine-to-arginine substitution in PBP1A induces high-level amoxicillin resistance in \(H.\ pylori\) (32), which may explain the increase in naturally occurring \(H.\ pylori\) strains with a high level of amoxicillin resistance in recent years. Currently, amoxicillin remains one of the first-line antibiotics used for prophylaxis and treatment of \(H.\ pylori\); however, the clinical significance of \(H.\ pylori_{CagA+/P_+}\) in GC remains largely unknown. The present study revealed
that *H. pylori* infection was significantly associated with various clinicopathological parameters, including invasion depth, lymphatic metastasis and distant metastasis. However, due to problems with follow-up, the 5 year overall or disease-free survival rates among the different *H. pylori* strain-infected cohorts were not analyzed. The present study hypothesized that *H. pylori* infection may be associated with a poorer outcome for patients with GC as compared to those with *H. pylori*-negative infection.

The present study further investigated the mechanisms underlying the clinical significance of *H. pylori* infection. EMT is a well-characterized embryological process that serves a critical role in tumor metastasis. EMT is characterized by the loss of epithelial markers (e.g., E-cadherin) and the acquisition of mesenchymal markers (e.g., Vimentin and α-SMA) (33). The present study revealed that *H. pylori* induced a significant increase in cell proliferation and invasion, a decrease in E-cadherin expression, and an increase in Vimentin and α-SMA expression. Furthermore, since emerging evidence has suggested that miRNAs serve an important role in the control of *H. pylori* infection-associated responses in GC (34), this study investigated whether miRNAs were involved in *H. pylori*-induced EMT in GC. To determine the miRNA expression profiles in *H. pylori*-associated GC, a microarray chip was used to measure miRNA expression levels in GC tissues with *H. pylori* or *H. pylori* infection. Notably, miR-134 was specifically downregulated in *H. pylori*-infected tissues compared with those with *H. pylori*-negative infection.

Aberrant levels of miR-134 have been detected in various malignancies, and may regulate tumor development, differentiation, proliferation, invasion and metastasis (35,36). Overexpression of miR-134 inhibits migration, invasion and EMT of lung cancer cells by targeting integrin β1 mRNA (37). Similarly, Zha et al revealed that miR-134 specifically targets integrin β1 to suppress the invasion and metastasis of hepatocellular carcinoma cells *in vitro* and *in vivo* (38). Additionally, forced expression of miR-134 inhibits the migration and invasion of renal cell carcinoma cells by blocking EMT (39). These findings indicated the miR-134 may serve as a tumor suppressor in human cancer (40); however, the pathogenetic roles of miR-134 were obscure in GC, particularly in GC associated with *H. pylori* infection. To the best of our knowledge, the current study was the first to reveal that forced overexpression of miR-134 could significantly reverse *H. pylori*-induced cell proliferation, invasion and EMT. Notably, the molecular and modulated mechanisms of miRNA are complex and variable (41), and a recent study revealed that miR-134 has diverse target genes in cancer (40). Using bioinformatics analysis and molecular experiments, the present study demonstrated that the downregulation of miR-134 in *H. pylori*-infected GC tissues was associated with upregulated FoxM1 mRNA and protein expression. In agreement with the sequence alignment, the luciferase reporter assays confirmed the direct targeting of the FoxM1 3′-untranslated region by miR-134, and suggested that a strong affinity may exist between miR-134 and FoxM1 mRNA in patients with GC and *H. pylori*-negative infection.
FoxM1 shares homology with the winged helix DNA-binding domain and is predominantly expressed in fetal tissue. It is maintained ubiquitously in all proliferating adult tissues and some cancer cell lines, whereas its expression is absent from differentiated cells (42). The role of FoxM1 in the progression of GC has previously been investigated. Promotion of gastric tumorigenesis by FoxM1 is directly and significantly correlated with transactivation of vascular endothelial growth factor expression and elevation of angiogenesis (43). Increased FOXM1 expression is also associated with invasive and metastatic processes in GC, and is inversely associated with patient prognosis (44). Mechanistically, FOXM1 promotes GC cell migration and invasion through inducing the expression of Cdh-D (45). Furthermore, a negative correlation has been identified between FoxM1 and E-cadherin expression in GC tissue (46). E-cadherin is associated with epithelial phenotypes, which serve a critical role in the process of EMT (47). In accordance with the previous study, the present results indicated that knockdown of FoxM1 significantly abolished H. pylori-induced EMT of SGC-7901 cells. The functional studies revealed that the effects of miR-134 on cell proliferation, invasion and EMT were reversed by FoxM1 overexpression. Although a previous study revealed that FoxM1 is overexpressed in H. pylori-CagA+ induced gastric carcinogenesis and is regulated by miR-370 (48), the present study is the first, to the best of our knowledge, to suggest that FoxM1 was involved in H. pylori-CagA+/P+ mediated GC cell EMT and was negatively controlled by miR-134, delineating the mechanisms governing FoxM1 regulation in GC.

The present study has numerous limitations. The number of clinical samples used in this study was relatively small and further studies are required to validate the role of H. pylori-CagA/P+ infection in patients with GC. Additionally, H. pylori infections in many patients are asymptomatic and only a few people develop clinical disease (49). However, focusing on the pathways implicated in H. pylori-induced tumorigenesis may lead to novel therapeutic strategies for GC prevention. In addition, with the growing proportion of amoxicillin-resistant H. pylori, a kit for detection of PBPIA mutations would be beneficial in clinical practice.

In conclusion, the present study revealed that H. pylori-CagA+/P+ was associated with poor clinicopathological characteristics.
in patients with GC. In addition, *H. pylori* cagA+P+ induced significant cell proliferation, invasion and EMT of GC cells. Mechanistically, *H. pylori* cagA+P+ promoted EMT of GC cells through suppressing miR-134, which targeted FoxM1 in GC.

Acknowledgements

Not applicable.

Funding

The study was supported by Natural Science Funding of China (grant nos. 31671869, 31471598, 31571852 and 31601487).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

DDP designed the study and performed the statistical analysis; LH and ZYW performed the experiments and data correction; LH wrote the manuscript.

Ethics approval and consent to participate

The present study was approved by the ethical board of the Jiangsu Province Hospital of TCM (ethical no. JSSZY Y2014085). All studies performed involving human participants were conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, and the 2013 Declaration of Helsinki. The patients, or their parents, provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E366, 2015.

2. Choi JI, Jook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B and Nam BH: *Helicobacter pylori* Theraoy for the Prevention of Metachronous Gastric Cancer. N Engl J Med 378: 1085-1095, 2018.

3. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrera L, Lazzano-Ponce EC, *et al.*: 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: A randomised trial. Lancet 378: 507-514, 2011.

4. Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS and Graham DY: Association Between *Helicobacter pylori* Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 150: 1113-1124.e5, 2016.

5. Wang F, Sun G, Zou YF, Zhong F, Ma T and Li XQ: miR-134 for patients with gastric cancer. PLoS One 8: e62440, 2013.

6. Wang F, Sun G, Zou Y, Zhong F, Ma T and Li X: Protective role of *Helicobacter pylori* infection in prognosis of gastric cancer: Evidence from 2,454 patients with gastric cancer. PLoS One 8: e62440, 2013.

7. Zheng F, Sun Z, Kan J, Yin J, Du F, Shen G, Wang Z, Ren D, Bao X and Zhao J: Is It a Protective Factor of *Helicobacter pylori* Infection in Overall Survival of All Gastric Cancer? Evidence from Meta-Analysis. J Environ Pathol Toxicol Oncol 36: 309-320, 2017.

8. Varga MG, Wang T, Cai H, Xiang YB, Gao YT, Ji BT, Pawliita M, Waterboer T, Zheng W, Shu XO, *et al.*: *Helicobacter pylori* Blood Biomarkers and Gastric Cancer Survival in China. Cancer Epidemiol Biomarkers Prev 27: 342-344, 2018.

9. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Ginsinis LF, Gisbert JP, Graham DY, Kokkas T, *et al.* European Helicobacter Study Group: Management of *Helicobacter pylori* infection - the Maastricht IV/Florence Consensus Report. Gut 61: 646-664, 2012.

10. Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martinez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazzano-Ponce EC, *et al.* Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 309: 578-586, 2013.

11. Nagai K, Davies TA, Jacobs MR and Appelbaum PC: Effects of amino acid alterations in penicillin-binding proteins (PBP)s 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefotetrone, cefuroxime, cefpodoxim, and cefaclor in 18 clinical isolates of penicillin-resistant, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 46: 1273-1280, 2002.

12. Polk DB and Peek RM Jr: *Helicobacter pylori*: Gastric cancer and beyond. Nat Rev Cancer 10: 403-414, 2010.

13. Park JY, Forman D, Waskito LA, Yamaoka Y and Crabtree JE: Epidemiology of *Helicobacter pylori* and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel) 10: 10, 2018.

14. Yong X, Tang B, Li BS, Xie R, Hu CJ, Luo G, Qin Y, Dong H and Yang SM: *Helicobacter pylori* virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal 13: 30, 2015.

15. Sokolova O, Borgmann M, Rieke C, Schweitzer K, Rothkötter HJ and Naumann M: *Helicobacter pylori* induces type 4 secretion system-dependent, but CagA-independent activation of IkBs and NF-κBRelA at early time points. Int J Med Microbiol 303: 548-552, 2013.

16. Yoon JH, Seo HS, Choi SS, Chae HS, Choi WS, Kim O, Ashktorab H, Smoot DT, Nam SW, Lee JY, *et al.*: Gastrokine 1 inhibits the carcinogenic potentials of *Helicobacter pylori* CagA. Carcinogenesis 35: 2619-2629, 2014.

17. Cadamurom AC, Rossi AF, Maniezio MM and Silva AE: *Helicobacter pylori* infection: Host immune response, implications on gene expression and microRNAs. World J Gastroenterol 20: 1424-1437, 2014.

18. Verma R and Sharma PC: Next generation sequencing-based emerging trends in molecular biology of gastric cancer. Am J Cancer Res 8: 207-225, 2018.

19. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, *et al.*: Relative microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Cancer Res 110: 136-146, 2010.

20. Shi JY, Leung WK, Cheng AF, Sung YJ, Ling TK, Ling JM, Xie WK, Lau JY and Chung SC: Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for *Helicobacter pylori*. J Clin Microbiol 36: 3048-3050, 1998.

21. Atirso-Morales J, Martinez-Santos VI, Román-Román A, Alarcón-Milán J.D, Sampedro-Reyes J, Cruz-del Carmen I, Martínez-Carrillo DN and Fernández-Tilapa G: vacA s1m1 genotype and cagA EPIYA-ABC pattern are predominant among *Helicobacter pylori* strains isolated from Mexican patients with chronic gastritis. J Med Microbiol 67: 314-324, 2018.

22. Kwon YH, Kim YJ, Kim N, Park JH, Nam RH, Lee SM, Kim KW, Kim JH, Park JY and Lee DH: Specific mutations of penicillin-binding protein 1A in 77 clinically acquired amoxi...
24. Qureshi NN, Gallaher B and Schiller NL: Evolution of amoxicillin resistance of *Helicobacter pylori* in vitro: Characterization of resistance mechanisms. Microb Drug Resist 20: 509-516, 2014.

25. Al-Maleki AR, Loke MF, Liu SY, Ramli NSK, Khorasvi Y, Ng CG, Venkatraman G, Goh KL, Ho B and Vadivelu J: *Helicobacter pylori* outer inflammatory protein A (OipA) suppresses apoptosis of AGS gastric cells in vitro. Cell Microbiol 19: 19, 2017.

26. Yang J, Song H, Cao K, Song J and Zhou J: Comprehensive analysis of *Helicobacter pylori* infection-associated diseases based on miRNA-mRNA interaction network. Brief Bioinform: Mar 20, 2018 (Epub ahead of print).

27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

28. Yang Y, Li X, Du J, Yin Y and Li Y: Involvement of microRNAs-MMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with *Helicobacter pylori*. Exp Cell Res 367: 196-204, 2018.

29. Tsai KF, Liou JM, Chen MJ, Chen CC, Kuo SH, Lai IR, Yeh KH, Lin MT, Wang HP, Cheng AL, et al: Taiwan Gastrointestinal Disease and Helicobacter Consortium: Distinct Clinicoopathological Features and Prognosis of *Helicobacter pylori* Negative Gastric Cancer. PLoS One 12: e0170942, 2017.

30. DeLoney CR and Schiller NL: Characterization of an In vitro-selected amoxicillin-resistant strain of *Helicobacter pylori*. Antimicrob Agents Chemother 44: 3368-3373, 2000.

31. Paul R, Postius S, Melchers K and Schäfer KP: Mutations of the *pylori* N-methyltransferase promotes epithelial-mesenchymal transition in gastric cancer cells by activating transforming growth factor-β1 expression. Oncol Lett 15: 4592-4598, 2018.

32. Polakovicova I, Jerez S, Wichmann IA, Sandoval-Bórquez A, Carrasco-Véliz N and Corvalán AH: Role of microRNAs and Exosomes in *Helicobacter pylori* and Epstein-Barr Virus Associated Gastric Cancers. Front Microbiol 9: 636, 2018.

33. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y and Yu W: miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett 580: 3761-3765, 2012.

34. Liu CJ, Shen WG, Peng SY, Cheng HW, Kao SY, Lin SC and Chang KW: miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer 134: 811-821, 2014.

35. Qin Q, Wei F, Zhang J and Li B: miR-134 suppresses the migration and invasion of non small cell lung cancer by targeting ITGB1. Oncol Rep 37: 823-830, 2017.

36. Zha R, Guo W, Zhang Z, Qiu Z, Wang Q, Ding J, Huang S, Chen T, Gu J, Yao M, et al: Genome-wide screening identified that miR-134 acts as a metastasis suppressor by targeting integrin β1 in hepatocellular carcinoma. PLoS One 9: e87665, 2014.

37. Liu Y, Zhang M, Qian J, Bao M, Meng X, Zhang S, Zhang L, Zhao R, Li S, Cao Q, et al: miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. DNA Cell Biol 34: 429-436, 2015.

38. Pan YJ, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, et al: miR-134: A Human Cancer Suppressor? Mol Ther Nucleic Acids 6: 140-149, 2017.

39. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.

40. Korver W, Roose J and Clevers H: The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res 25: 1715-1719, 1997.

41. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, Huang S, Tan D and Xie K: Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 69: 3501-3509, 2009.

42. Ma J, Qi G, Xu J, Ni H, Xu W, Ru G, Zhao Z, Xu W and He X: Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis. Oncol Lett 14: 7288-7296, 2017.

43. Yang L, Cui M, Zhang L and Song L: FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D. Oncotarget 8: 68180-68190, 2017.

44. Zhang J, Chen XY, Huang KJ, Wu WD, Jiang T, Cao J, Zhou LS, Qiu ZJ and Huang C: Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance. Oncol Lett 12: 2445-2450, 2016.

45. Yu H, Shen Y, Hong J, Xia Q, Zhou F and Liu X: The contribution of TGF-β in Epithelial-Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail. Neoplasma 62: 1-15, 2015.

46. Feng Y, Wang L, Zeng J, Shen L, Liang X, Yu H, Liu S, Liu Z, Sun Y, Li W, et al: FoxM1 is overexpressed in *Helicobacter pylori*-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res 11: 834-844, 2013.

47. Gunawardhana N, Jang S, Choi YH, Hong YA, Jeon YE, Kim A, Su H, Kim JH, Yoo YJ, Merrell DS, et al: *Helicobacter pylori*-Induced HB-EGF Upregulates Gastrin Expression via the EGF Receptor, C-Raf, Mek1, and Erk2 in the MAPK Pathway. Front Cell Infect Microbiol 7: 541, 2018.